Currently, there are 98.77M common shares owned by the public and among those 67.72M shares have been available to trade.
The company’s stock has a 5-day price change of -8.74% and -23.77% over the past three months. CNTA shares are trading 6.97% year to date (YTD), with the 12-month market performance up to 49.91% higher. It has a 12-month low price of $4.91 and touched a high of $12.45 over the same period. CNTA has an average intraday trading volume of 215.91K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.67%, -9.79%, and 2.23% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) shares accounts for 37.38% of the company’s 98.77M shares outstanding.
It has a market capitalization of $855.59M and a beta (3y monthly) value of 1.42. The earnings-per-share (ttm) stands at -$1.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.10% over the week and 5.91% over the month.
Earnings per share for the fiscal year are expected to decrease by -2.44%, and -1.76% over the next financial year.
Looking at the support for the CNTA, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on November 15, 2023, with the firm’s price target at $4-$11. Morgan Stanley coverage for the Centessa Pharmaceuticals plc ADR (CNTA) stock in a research note released on October 26, 2023 offered a Equal-Weight rating with a price target of $8. Evercore ISI was of a view on June 21, 2023 that the stock is Outperform, while Guggenheim gave the stock Buy rating on June 12, 2023, issuing a price target of $9. SVB Securities on their part issued Outperform rating on March 17, 2023.
